urothelial carcinoma

This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.

Positive first-line phase 3 results for Tecentriq

advanced or metastatic urothelial carcinoma (mUC). Urothelial carcinoma is the most common type of bladder cancer, and accounts for around 90% of cases, with 30% of those considered to be advanced.

Latest news

Lilly to withdraw Lartruvo, a first for accelerated approval failures

In recent times, several immunotherapy treatments have failed confirmatory studies. These include Roche’s Tecentriq and others in urothelial carcinoma, and Merck &Co’s Keytruda in gastric cancer, however the FDA
J&J’s targeted bladder cancer treatment gets US approval

We recognise the significant unmet need that persists in the treatment of men and women diagnosed with this form of urothelial carcinoma, and we have worked expeditiously to develop Balversa for ... We look forward to the continued development of
NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Imfinzi is far behind that tally, with 2018 sales of $633m, based largely on its first indication, urothelial carcinoma.
BMS presses go on Nektar combo pivotal trials, despite data debate

The phase I/II PIVOT trial met the criteria needed to advance PD-1 inhibitor Opdivo (nivolumab) and CD122-biased agonist NKTR0214 into pivotal trials in melanoma, renal cell carcinoma and ... Nektar and BMS also reported initial stage 1 data in
Keytruda gains NICE clearance in first line bladder cancer

Cost effectiveness watchdog NICE issued a Final Appraisal Determination (FAD) on Friday, recommending MSD’s treatment within the cancer drugs fund (CDF) for untreated locally advanced or metastatic urothelial carcinoma in ... Pembrolizumab is already

More from news
Approximately 2 fully matching, plus 26 partially matching documents found.

Latest Intelligence

Europe vs the US: New drug product approvals

Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Account Director – UK Office: Excellent salary and benefits

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director, Healthcare Communications: Salary TBC

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
The evolution of real-world studies: How industry and regulators are using real-world data...